Goldman Sachs
AURA icon

Goldman Sachs’s Aura Biosciences AURA Stock Holding History

Goldman Sachs’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
178,726
+38,800
+28% +$223K ﹤0.01% 4969
2025
Q4 		$763K Sell
139,926
-55,017
-28% -$327K ﹤0.01% 5319
2025
Q3 		$1.2M Sell
194,943
-17,355
-8% -$113K ﹤0.01% 4896
2025
Q2 		$1.33M Buy
212,298
+90,654
+75% +$530K ﹤0.01% 4498
2025
Q1 		$713K Sell
121,644
-32,410
-21% -$245K ﹤0.01% 4943
2024
Q4 		$1.27M Buy
154,054
+40,082
+35% +$377K ﹤0.01% 4649
2024
Q3 		$1.02M Sell
113,972
-915,949
-89% -$7.85M ﹤0.01% 4622
2024
Q2 		$7.79M Buy
1,029,921
+33,278
+3% +$244K ﹤0.01% 2747
2024
Q1 		$7.82M Sell
996,643
-40,656
-4% -$337K ﹤0.01% 2704
2023
Q4 		$9.19M Buy
1,037,299
+44,097
+4% +$373K ﹤0.01% 2611
2023
Q3 		$8.91M Sell
993,202
-33,702
-3% -$363K ﹤0.01% 2488
2023
Q2 		$12.7M Buy
1,026,904
+738,406
+256% +$7.89M ﹤0.01% 2225
2023
Q1 		$2.68M Buy
288,498
+82,918
+40% +$861K ﹤0.01% 3617
2022
Q4 		$2.16M Buy
+205,580
New +$2.62M ﹤0.01% 3885

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs's AURA Position: Q1 2026 in Review

Goldman Sachs increased its Aura Biosciences (AURA) stake by 28% in Q1 2026, buying an estimated $223K and bringing the position to 178,726 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #4969.

Goldman Sachs first reported a position in AURA in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.7M in Q2 2023. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Goldman Sachs held 178,726 shares of Aura Biosciences worth $1.2M as of Q1 2026.
  • Goldman Sachs bought 38,800 Aura Biosciences shares in Q1 2026, an estimated $223K.
  • Aura Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4969 holding.
  • Goldman Sachs first reported a position in Aura Biosciences in Q4 2022 and has held it in 14 quarters since.
  • Goldman Sachs's Aura Biosciences position peaked at $12.7M in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.